All the news

Almost half of people with HIV with unexplained liver enzyme elevations or other abnormal liver markers had non-alcoholic steatohepatitis (NASH) and 39 of 116 had stage F3 or F4 fibrosis, and advanced ...

Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving sustained virological response to hepatitis C treatment, according to studies presented at the recent 2020 Digital ...

People with advanced liver cirrhosis are more likely to develop severe COVID-19 complications and to die from it, but those who have received liver transplants do not appear to be at greater ...

Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ...

Non-alcoholic fatty liver disease affects one in four people in the general population in Europe and just over one in twenty people have advanced liver fibrosis, a meta-analysis of 33 studies from ...

Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ...

Three checkpoint inhibitor immunotherapy regimens show promise for people with hepatocellular carcinoma (HCC), the most common type of liver cancer, according to a set of late-breaking presentations last week at the 2020 Digital ...

Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ...

High-dose bulevirtide (Hepcludex) combined with pegylated interferon alfa-2a (Pegasys) or tenofovir disoproxil fumarate (TDF; Viread) led to suppression of hepatitis delta virus (HDV), according to a presentation this week at the 2020 Digital International ...

Johnson & Johnson’s short interfering RNA treatment for hepatitis B resulted in sustained reductions in hepatitis B surface antigen when combined with nucleoside analogue drugs, Professor Edward Gane of Auckland City Hospital, New ...